The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A new 50-gene molecular subtype classifier: An evaluation of subtype stability and association with response to neoadjuvant chemotherapy in muscle-invasive bladder cancer.
 
Woonyoung Choi
No Relationships to Disclose
 
Elizabeth R. Plimack
Consulting or Advisory Role - Acceleron Pharma; Acceleron Pharma; AstraZeneca/MedImmune; Bristol-Myers Squibb; Exelixis; Genentech/Roche; Horizon Pharma; Inovio Pharmaceuticals; Lilly; Novartis; Pfizer
Research Funding - Agensys (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst); Peloton Therapeutics (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - U.S. Patent No.: 14/588,503, Filed 1/2/2015. (Inst); US Patent No: 15/226,474 files on 7/1/15 (Inst)
 
Arlene O. Siefker-Radtke
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Eisai; EMD Serono; Genentech; Inovio Pharmaceuticals; Janssen; Lilly; Merck; NCCN
Speakers' Bureau - Genentech
Research Funding - Bristol-Myers Squibb; Janssen; Michael and Sherry Sutton Fund for Urothelial Cancer; NIH; Takeda
Patents, Royalties, Other Intellectual Property - Methods of characterizing and treating molecular subsets of muscle-invasive bladder cancer.
 
Colin P.N. Dinney
Honoraria - Merck Sharp & Dohme
Consulting or Advisory Role - FKD Therapies; Genentech; Merck Sharp & Dohme
Research Funding - FKD Therapies
Travel, Accommodations, Expenses - Genentech; Merck Sharp & Dohme
 
David James McConkey
Stock and Other Ownership Interests - Apocell